FKBP51s signature in peripheral blood mononuclear cells of melanoma patients as a possible predictive factor for immunotherapy.

摘要: The inhibitory immune checkpoint PD-L1/PD1 promotes the alternative splicing of FKBP5 gene, resulting in increased expression its variant 4 peripheral blood mononuclear cells melanoma patients. transcript is translated into truncated FKBP51s protein. Given importance co-inhibitory signalling tumour escape, here we tested potential for using to predict immunotherapy outcomes. To do this, immunophenotyped PBMCs from 118 patients and 77 age- sex-matched healthy controls. Blood samples were collected before underwent ipilimumab treatment. In 64 patients, was also assessed regulatory T (Tregs). We found that each PBMC subset analysed contained an FKBP51spos fraction, this fraction greater than CD4 lymphocytes, FKBP51sneg significantly impaired. Tregs count which line with previous studies. Also, by analyses Tregs, identified a subgroup nonresponder (p = 0.002). conclusion, FKBP51s-based immunophenotyping revealed several profiles related negative control unknown Treg subset. These findings are likely be useful selection candidate immunotherapy.